In vivo activation of transferred regulatory T cells specific for third-party exogenous antigen controls GVH disease in mice

European Journal of Immunology

Volumn 43, Issue 9, 2013, Pages 2263-2272

  Martin, Gaëlle H ^a   Grégoire, Sylvie ^a   Landau, Dan A ^b,c   Pilon, Caroline ^a   Grinberg Bleyer, Yenkel ^a   Charlotte, Frédéric ^d   Mège, Jean Pierre ^e   Chatenoud, Lucienne ^f   Salomon, Benoît L ^a   Cohen, José L ^e,g,h  

^a INSERM   (France)

^b YALE CANCER CENTER   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^h INSERM U955   (France)

Author keywords

GVH disease; Immune regulation; Inducible activation of regulatory T (Treg) cells; Tolerance; Transplantation

Indexed keywords

ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BYSTANDER EFFECT; CELL SUSPENSION; CONTROLLED STUDY; EFFECTOR CELL; EX VIVO STUDY; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HISTOLOGY; IMMUNOREGULATION; IN VIVO STUDY; MALE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RISK REDUCTION; SKIN GRAFT; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION;

GVH DISEASE; IMMUNE REGULATION; INDUCIBLE ACTIVATION OF REGULATORY T (TREG) CELLS; TOLERANCE; TRANSPLANTATION;

ANIMALS; FEMALE; GRAFT VS HOST DISEASE; H-Y ANTIGEN; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS;

EID: 84883528115     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201343449     Document Type: Article

References (45)

1. Thomas, E., Storb, R., Clift, R. A., Fefer, A., Johnson, F. L., Neiman, P. E., Lerner, K. G. et al., Bone-marrow transplantation (first of two parts). N. Engl. J. Med. 1975. 292: 832-843.
2. Martin, P. J., Hansen, J. A., Buckner, C. D., Sanders, J. E., Deeg, H. J., Stewart, P., Appelbaum, F. R. et al., Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 1985. 66: 664-672.
3. Mackall, C. L. and Gress, R. E., Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Immunol. Rev. 1997. 157: 61-72.
4. Horowitz, M. M., Gale, R. P., Sondel, P. M., Goldman, J. M., Kersey, J., Kolb, H. J., Rimm, A. A. et al., Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990. 75: 555-562.
5. Amarnath, S., Costanzo, C. M., Mariotti, J., Ullman, J. L., Telford, W. G., Kapoor, V., Riley, J. L. et al., Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. PLoS Biol. 2010. 8: e1000302.
6. Ferrara, J. L., Levine, J. E., Reddy, P. and Holler, E., Graft-versus-host disease. Lancet 2009. 373: 1550-1561.
7. Ratanatharathorn, V., Nash, R. A., Przepiorka, D., Devine, S. M., Klein, J. L., Weisdorf, D., Fay, J. W. et al., Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998. 92: 2303-2314.
8. Storb, R., Deeg, H. J., Pepe, M., Appelbaum, F., Anasetti, C., Beatty, P., Bensinger, W., et al., Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989. 73: 1729-1734.
9. Bhatia, S., Francisco, L., Carter, A., Sun, C. L., Baker, K. S., Gurney, J. G., McGlave, P. B. et al., Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007. 110: 3784-3792.
10. Socie, G., Stone, J. V., Wingard, J. R., Weisdorf, D., Henslee-Downey, P. J., Bredeson, C., Cahn, J. Y. et al., Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N. Engl. J. Med. 1999. 341: 14-21.
11. Taylor, P. A., Lees, C. J. and Blazar, B. R., The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002. 99: 3493-3499.
12. Cohen, J. L., Trenado, A., Vasey, D., Klatzmann, D. and Salomon, B. L., CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J. Exp. Med. 2002. 196: 401-406.
13. Trenado, A., Charlotte, F., Fisson, S., Yagello, M., Klatzmann, D., Salomon, B. L. and Cohen, J. L., Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J. Clin. Invest. 2003. 112: 1688-1696.
14. Taylor, P. A., Panoskaltsis-Mortari, A., Swedin, J. M., Lucas, P. J., Gress, R. E., Levine, B. L., June, C. H. et al., L-Selectin(hi) but not the L-selectin(lo) CD4+25 +T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 2004. 104: 3804-3812.
15. Ermann, J., Hoffmann, P., Edinger, M., Dutt, S., Blankenberg, F. G., Higgins, J. P., Negrin, R. S. et al., Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 2005. 105: 2220-2226.
16. Trenado, A., Sudres, M., Tang, Q., Maury, S., Charlotte, F., Gregoire, S., Bonyhadi, M. et al., Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. J. Immunol. 2006. 176: 1266-1273.
17. Sagoo, P., Ratnasothy, K., Tsang, Y., Barber, L. D., Noble, A., Lechler, R. I. and Lombardi, G., Alloantigen-specific regulatory T cells prevent experimental chronic graft-versus-host disease by simultaneous control of allo- and autoreactivity. Eur. J. Immunol. 2012. 42: 3322-3333.
18. Di Ianni, M., Falzetti, F., Carotti, A., Terenzi, A., Castellino, F., Bonifacio, E., Del Papa, B. et al., prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011. 117: 3921-3928.
19. Brunstein, C. G., Miller, J. S., Cao, Q., McKenna, D. H., Hippen, K. L., Curtsinger, J., Defort, T. et al., Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011. 117: 1061-1070.
20. Sagoo, P., Ali, N., Garg, G., Nestle, F. O., Lechler, R. I. and Lombardi, G., Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci. Transl. Med. 2011. 3: 83ra42.
21. Tang, Q., Henriksen, K. J., Bi, M., Finger, E. B., Szot, G., Ye, J., Masteller, E. L. et al., In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 2004. 199: 1455-1465.
22. Tarbell, K. V., Yamazaki, S., Olson, K., Toy, P. and Steinman, R. M., CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med. 2004. 199: 1467-1477.
23. Gaidot, A., Landau, D. A., Martin, G. H., Bonduelle, O., Grinberg-Bleyer, Y., Matheoud, D., Gregoire, S. et al., Immune reconstitution is preserved in hematopoietic stem cell transplant co-administered with regulatory T cells for GVHD prevention. Blood 2011. 117: 2975-2983.
24. Fisson, S., Djelti, F., Trenado, A., Billiard, F., Liblau, R., Klatzmann, D., Cohen, J. L. et al., Therapeutic potential of self-antigen-specific CD4+ CD25+ regulatory T cells selected in vitro from a polyclonal repertoire. Eur. J. Immunol. 2006. 36: 817-827.
25. Tang, Q. and Bluestone, J. A., The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol. 2008. 9: 239-244.
26. Boyman, O., Letourneau, S., Krieg, C. and Sprent, J., Homeostatic proliferation and survival of naive and memory T cells. Eur. J. Immunol. 2009. 39: 2088-2094.
27. Su, Y., Huang, X., Wang, S., Min, W. P., Yin, Z., Jevnikar, A. M. and Zhang, Z. X., Double negative Treg cells promote nonmyeloablative bone marrow chimerism by inducing T-cell clonal deletion and suppressing NK cell function. Eur. J. Immunol. 2012. 42: 1216-1225.
28. Thornton, A. M. and Shevach, E. M., Suppressor effector function of CD4+CD25+immunoregulatory T cells is antigen nonspecific. J. Immunol. 2000. 164: 183-190.
29. Maury, S., Salomon, B., Klatzmann, D. and Cohen, J. L., Division rate and phenotypic differences discriminate alloreactive and nonalloreactive T cells transferred in lethally irradiated mice. Blood 2001. 98: 3156-3158.
30. Katz, J. D., Wang, B., Haskins, K., Benoist, C. and Mathis, D., Following a diabetogenic T cell from genesis through pathogenesis. Cell 1993. 74: 1089-1100.
31. Stephens, L. A., Malpass, K. H. and Anderton, S. M., Curing CNS autoimmune disease with myelin-reactive Foxp3+ Treg. Eur. J. Immunol. 2009. 39: 1108-1117.
32. Wright, G. P., Notley, C. A., Xue, S. A., Bendle, G. M., Holler, A., Schumacher, T. N., Ehrenstein, M. R. et al., Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc. Natl. Acad. Sci. USA 2009. 106: 19078-19083.
33. Karim, M., Feng, G., Wood, K. J. and Bushell, A. R., CD25+CD4+ regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: antigen-specific reactivation in vivo is critical for bystander regulation. Blood 2005. 105: 4871-4877.
34. Verginis, P., McLaughlin, K. A., Wucherpfennig, K. W., von Boehmer, H. and Apostolou, I., Induction of antigen-specific regulatory T cells in wild-type mice: visualization and targets of suppression. Proc. Natl. Acad. Sci. USA 2008. 105: 3479-3484.
35. Hoffmann, P., Eder, R., Kunz-Schughart, L. A., Andreesen, R. and Edinger, M., Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood 2004. 104: 895-903.
36. Hoffmann, P., Boeld, T. J., Eder, R., Albrecht, J., Doser, K., Piseshka, B., Dada, A. et al., Isolation of CD4+CD25+ regulatory T cells for clinical trials. Biol. Blood Marrow Transplant 2006. 12: 267-274.
37. Hoffmann, P., Eder, R., Boeld, T. J., Doser, K., Piseshka, B., Andreesen, R. and Edinger, M., Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 2006. 108: 4260-4267.
38. Roncarolo, M. G. and Battaglia, M., Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat. Rev. Immunol. 2007. 7: 585-598.
39. Hoffmann, P., Boeld, T. J., Eder, R., Huehn, J., Floess, S., Wieczorek, G., Olek, S. et al., Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur. J. Immunol. 2009. 39: 1088-1097.
40. Nadig, S. N., Wieckiewicz, J., Wu, D. C., Warnecke, G., Zhang, W., Luo, S., Schiopu, A. et al., In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat. Med. 2010. 16: 809-813.
41. Roncarolo, M. G., Gregori, S., Lucarelli, B., Ciceri, F. and Bacchetta, R., Clinical tolerance in allogeneic hematopoietic stem cell transplantation. Immunol. Rev. 2011. 241: 145-163.
42. Tresoldi, E., Dell'albani, I., Stabilini, A., Jofra, T., Valle, A., Gagliani, N., Bondanza, A. et al., Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells. Haematologica 2011. 96: 1357-1365.
43. Hippen, K. L., Merkel, S. C., Schirm, D. K., Sieben, C. M., Sumstad, D., Kadidlo, D. M., McKenna, D. H. et al., Massive ex vivo expansion of human natural regulatory T cells (Tregs) with minimal loss of in vivo functional activity. Sci. Transl. Med. 2011. 3: 83ra41.
44. Edinger, M. and Hoffmann, P., Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. Curr. Opin. Immunol. 2011. 23: 679-684.
45. Hill, G. R. and Ferrara, J. L., The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000. 95: 2754-2759.